Cambridge, MA's NeuroPhage banked an additional $10 million in Series D cash, bringing its latest round to $27 million and filling out the biotech's war chest as it marches toward the clinic with a treatment for neurodegenerative disease. The new cash will support NPT088, a drug that targets the protein misfolding at the heart of Alzheimer's and Parkinson's diseases, unblinding the body's defenses to spur a natural response to toxic buildups. NeuroPhage plans to get its top prospect into Phase I trials by the end of this year, all the while working on next-generation therapies based on the same platform. More